Clinical trial
A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection.
NCT00389298 · Vertex Pharmaceuticals Incorporated, Industry · Completed
Key facts
| NCT number | NCT00389298 |
|---|---|
| Title | A Proof-of-concept Study of VCH-759 for the Treatment of Hepatitis C-infection. |
| Official title | A Phase 2, Multicenter, Randomized, Double-blinded, and Placebo-controlled Study of the Antiviral Activity, Safety and Pharmacokinetics of VCH-759 in Subjects With Chronic Hepatitis C-infection. |
| Lead sponsor | Vertex Pharmaceuticals Incorporated, Industry |
| Collaborators | ViroChem Pharma Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C, Chronic |
| Intervention type | Drug |
| Interventions | VCH-759 (BCH-27759) |
| Enrollment | 36 |
| Start date | Oct 1, 2006 |
| Completion | Jun 1, 2007 |
| First posted | Oct 18, 2006 |
| Last update posted | Sep 24, 2009 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: